COCH Envoy Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1840877 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY4.3%
TTM EPS YoY164.4%
Revenue 3-yr CAGR-1.4%
Net income 3-yr CAGR—
Margins
Gross margin-352.8%
Operating margin-10,151.5%
Net margin-9,026.4%
FCF margin—
EBITDA margin-10,020.8%
Returns
ROE—
ROA-152.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio1.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $241,000 | $225,000 | $316,000 | $237,000 | — |
| Cost of revenue | $874,000 | $742,000 | $789,000 | $498,000 | — |
| Gross profit | -$633,000 | -$517,000 | -$473,000 | -$261,000 | — |
| R&D expense | $12.49M | $10.18M | $8.96M | $4.97M | — |
| SG&A expense | $7.93M | $6.83M | $7.26M | $2.58M | — |
| Operating income | -$22.27M | -$19.26M | -$18.36M | -$8.71M | -$5.20M |
| Interest expense | $1.59M | $816,000 | — | — | — |
| Pretax income | -$23.76M | -$20.80M | — | $20.74M | -$251,633 |
| Income tax | — | — | — | $1.50M | — |
| Net income | -$23.76M | -$20.80M | -$29.92M | -$15.92M | -$251,633 |
| EBITDA | -$21.97M | -$19.08M | -$18.23M | -$8.63M | — |
| EPS (basic) | -1.23 | -1.49 | -2.54 | -1.57 | — |
| EPS (diluted) | -1.23 | -1.49 | -2.54 | -1.57 | — |
| Weighted avg. shares (diluted) | 23.26M | 18.79M | 12.30M | 10.12M | — |
| Balance sheet | |||||
| Cash & equivalents | $3.74M | $5.48M | $4.22M | $183,000 | $1.12M |
| Receivables | $34,000 | $38,000 | $70,000 | $41,000 | — |
| Inventory | $1.55M | $1.71M | $1.40M | $1.29M | — |
| Current assets | $6.28M | $8.90M | $7.46M | $1.65M | $863,167 |
| PP&E, net | $1.03M | $1.27M | $351,000 | $331,000 | — |
| Total assets | $8.56M | $11.54M | $8.27M | $2.56M | $426.90M |
| Current liabilities | $11.56M | $7.54M | $7.29M | $2.52M | $2.68M |
| Total liabilities | $20.32M | $30.38M | $10.05M | $38.75M | $38.62M |
| Shareholders' equity | -$12.16M | -$18.84M | -$1.78M | -$36.20M | -$44.96M |
| Shares outstanding | — | 21.33M | 18.60M | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$18.20M | -$17.95M | -$17.09M | -$8.80M | -$3.24M |
| Capital expenditure | $179,000 | $980,000 | $153,000 | $218,000 | — |
| Free cash flow | -$18.38M | -$18.93M | -$17.24M | -$9.02M | — |
| Investing cash flow | -$179,000 | -$980,000 | -$153,000 | -$218,000 | -$425.00M |
| Financing cash flow | $16.63M | $20.20M | $21.28M | $8.09M | $428.37M |
| Depreciation & amortization | $302,000 | $173,000 | $133,000 | $75,000 | — |
| Stock-based compensation | $657,000 | $562,000 | $1.57M | $0 | — |
| Dividends paid | $1.82M | $2.45M | — | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.